Led by the University of Oxford, a team of UK-based researchers have today reported results of the largest ever study to compare the risks of cardiovascular events, such as myocarditis, pericarditis, and cardiac arrhythmia, between different vaccines and COVID-19 infection, and the first to investigate the association between cardiac events and the Oxford-AstraZeneca vaccine.
Writing in Nature Medicine, the researchers linked the English National Immunisation (NIMS) Database of COVID-19 vaccination with a national patient level healthcare database of 38 million people aged 16 or older vaccinated for COVID-19 in England between 1 December 2020 and 24 August 2021. The study looked at rates of hospital admission or death from myocarditis, pericarditis, and cardiac arrhythmias in the 1–28 days following vaccination or a COVID-19 positive PCR test.
Julia Hippisley-Cox, professor of clinical epidemiology and general practice at the University of Oxford, and study lead said:
“We know the COVID-19 vaccines are highly effective at reducing risks of severe outcomes from COVID-19 infection. And what we’ve found here continues this finding—whilst there are some increased risks of rare heart related complications associated with vaccines these are much lower than the risk associated with getting COVID-19. For example, we estimated between 1 and 10 extra events of myocarditis in 1 million people vaccinated with a first or second dose, but 40 extra cases in 1 million people infected with COVID-19.
However, it is important that we know about and identify the risks of these rare conditions from vaccines as well, to ensure that clinicians know what to look for, aid earlier diagnosis, and inform clinical decision making and resource management.”
Martina Patone, medical statistician at the Nuffield Department of Primary Care Health Sciences, University of Oxford, and co-lead author said:
“This is the largest study to date of acute cardiac outcomes after COVID-19 vaccination or infection and the first to compare risk of cardiac events between different vaccine products and COVID-19 infection. This is also the first study to investigate the association between cardiac events and the Oxford AstraZeneca vaccine. This will be important to the public, clinicians and policy makers as although myocarditis and pericarditis were not observed as risks in COVID-19 vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population.”
The findings show the risks of myocarditis associated with the two mRNA vaccines to be slightly higher in people aged under 40 and particularly after the second Moderna vaccine. For these people, the study estimated that there were an extra 10 myocarditis events per million people following a positive SARS-CoV-2 test and an extra 15 per million following a second dose of mRNA-1273 (Moderna) vaccine.
The researchers stress that more research is needed to understand why the risk of myocarditis appears to be higher following the Moderna vaccine in this group of people, but also stress that while the risks of myocarditis are slightly higher than COVID-19 infection, the vaccine is still safer overall and risks less harm than COVID-19 infection.
Professor Nicholas Mills, British Heart Foundation Chair of Cardiology at the University of Edinburgh, and co-lead author said:
“Our findings are consistent with those from a similar study of people receiving the Pfizer-BioNTech vaccine from Israel and two studies of people receiving the Moderna vaccine in the US. We’ve now extended these observations by including 38 million adults in England receiving both adenovirus and mRNA vaccine types.
This study had several strengths. First, the UK offered an ideal place to carry out this study given three vaccinations have been rolled out at speed and scale. Second, this was a population-based study of prospectively recorded data and avoided recall and selection biases linked to case reports. Third, the large sample size means that we can identify rare events that might not be picked up through clinical trials.”
In an article published in the journal Science of the Total Environment, researchers have highlighted the significance and potential risks associated with the release of nanoparticles from coal-fired power plants. Applying the single-particle inductively coupled plasma mass [...]
A paper recently published in the journal ACS Applied Energy Materials demonstrated the feasibility of using a covalent organic framework (COF)-based nanofluidic hybrid membranes (NHMs) to attain enhanced interfacial ion transport for the generation of osmotic [...]
The excess fluoroquinolones (FQs) discharged into the aquatic environment due to human activities must be removed cost-effectively. In an article published in the Journal of Cleaner Production, the authors fabricated an environment-friendly dealkaline lignin-grafted Fe3O4 nanoparticles [...]
Controlling strong electromagnetic fields on nanoparticles is the key to triggering targeted molecular reactions on their surfaces. Such control over strong fields is achieved via laser light. Although laser-induced formation and breaking of molecular [...]
A paper recently published in the journal Nature Communications demonstrated an effective method to realize on-chip nanophotonic topological rainbow devices using the concept of synthetic dimensions. Importance of Synthetic Dimensions for the Construction of Topological Nanophotonics [...]
In a study available in the journal Materials Today: Proceedings, silver nanoparticles (Ag NPs) were fabricated using a green method using Citrus X sinensis. Methylthioninium Chloride (MB) Dyes Threatening the Environment Dye and sewage drainage into [...]
Public health experts are divided over how many people are getting long COVID-19, a potentially debilitating condition that comes after a patient has recovered from the coronavirus. Ill effects from the condition can include [...]
Well over two years into the pandemic, hundreds of thousands of COVID cases continue to be recorded around the world every day. With the rise of new variants, the symptoms of COVID have also evolved. Initially, [...]
Drug resistance is a common phenomenon, with drugs becoming less and less effective as their usage increases. To address this issue, a novel technique employing conjugated polymer-based nanoparticles is presented in the study published [...]
Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at [...]
Scientists have recently developed multifunctional hexagonal NaxWO3 nanocrystals that can serve as microwave sensitizers to kill cancer cells as well as improve the overall chemodynamic therapy (CDT). This study is available as a pre-proof in Chemical Engineering Journal. [...]
Apple’s visionary founder, the late Steve Jobs once said, “the biggest innovations of the 21st century will be at the intersection of biology and technology”. And that prediction is coming true in the drug [...]
Chemical separation processes are essential in the manufacturing of many products from gasoline to whiskey. Such processes are energetically costly, accounting for approximately 10–15 percent of global energy consumption. In particular, the use of [...]
Scientists have recently developed electrochemical immunosensors based on graphene oxide−gold (GO−Au) nanocomposites. These immunosensors are highly sensitive with dual function, i.e., they can detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen and antibody. [...]